Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Clinical Application of Leukocyte Counts Based on Targeted DNA Methylation Analysis

By LabMedica International staff writers
Posted on 14 Mar 2022

Leukocyte subsets are usually quantified with automated cell counting devices and particularly for stratification of lymphocyte subsets with flow cytometry. More...

Despite broad application, conventional methods have several limitations.

DNA methylation (DNAm) is a covalent modification of cytosine residues, mostly at CG dinucleotides (CpG sites). By measuring the methylation level at CpG sites with cell-type–specific hypo- or hypermethylation, it is possible to quantify the composition of leukocyte subsets using statistical algorithms (deconvolution models).

Biomedical Engineers at the RWTH Aachen University (Aachen, Germany) and colleagues optimized and validated targeted DNAm assays for leukocyte deconvolution using 332 venous and 122 capillary blood samples from healthy donors. In addition, they tested 36 samples from ring trials and venous blood from 266 patients diagnosed with different hematological diseases. Deconvolution of cell types was determined with various models using DNAm values obtained by pyrosequencing or digital droplet PCR (ddPCR).

DNA was isolated from 150 µL venous or 50 µL capillary blood and bisulfite-treated with the EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA). PCR amplicons were sequenced on a PyroMark Q96 ID (Qiagen, Hilden, Germany) and analyzed with Qiagen’s PyroMark Q96 CpG 1.0.9. Digital Droplet Polymerase Chain Reaction (ddPCR) was carried out with the QX200 Droplet Digital reader (Bio-Rad, Hercules, CA, USA). Absolute leukocyte quantification by pyrosequencing was also performed.

The investigators reported that relative leukocyte quantification correlated with conventional blood counts for granulocytes, lymphocytes, B cells, T cells (CD4 or CD8), natural killer cells, and monocytes with pyrosequencing and ddPCR measurements. In some patients, particularly with hematopoietic malignancies, they observed outliers in epigenetic leukocyte counts, which could be discerned if relative proportions of leukocyte subsets did not sum up to 100%. Furthermore, absolute quantification was obtained by spiking blood samples with a reference plasmid of known copy number. The results confirmed cell-type–specific hypomethylation in the genes WDR20, CD4, CD8A, WIPI2, SLC15A4, and CENPA, which was more pronounced compared to the Illumina BeadChip data or reverse nonnegative least square (NNLS) estimation.

The authors concluded that targeted DNAm analysis by pyrosequencing or ddPCR is a valid alternative to quantify leukocyte subsets, but some assays require further optimization. The study was published on February 14, 2022 in the journal Clinical Chemistry.

Related Links:
RWTH Aachen University 
Zymo Research 
Qiagen 
Bio-Rad 

 

 


New
Gold Member
Hybrid Pipette
SWITCH
Portable Electronic Pipette
Mini 96
Gel Cards
DG Gel Cards
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.